Immune system, infectious diseases Body’s defense system, infections
Conditions
Interventions
Not applicable.
Sponsors
RIVM
Eligibility
Age
No minimum to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a participant must meet all of the following criteria:Participant is part of the study sample drawn from the BRP OR the participant has participated in the previous PIENTER-3 study and PICO study and has given permission to be approached for follow-up research via the informed consent form;Has received a personal invitation for the PIENTER-4 study;Participants >16 years of age; Be capacitated;Presence of a signed (e-)informed consent form.Specific inclusion criteria Group 1:Aged = 2 years;Resident of the Netherlands including residents of the Dutch Wadden Islands (Texel, Vlieland, Terschelling, Ameland and Schiermonnikoog);Specific inclusion criteria Group 2:All ages;Residents of the Netherlands not including residents of the Dutch Wadden Islands (Texel, Vlieland, Terschelling, Ameland and Schiermonnikoog);Specific inclusion criteria Group 3:All ages;Resident of the selected municipalities with low vaccination coverage (i.e., <80% for measles-mumps-rubella (MMR)) where socio-geographically more Orthodox-Reformed Protestants reside.
Exclusion criteria
Exclusion criteria: There are no exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.1 The overall and age-specific seroprevalence against infectious diseases included in the NIP and candidate NIP-related among the general Dutch population as well as risk groups, insights into potential related risk factors pathogens, and incidence of vaccine-breakthrough infections during the study period. 1.2 Prevalence and risk factors for other infectious diseases among the general Dutch population.1.3 Retrospective infection prevalence and incidence of vaccine and non-vaccine-preventable infectious diseases.1.4 Investigate the duration of protection against vaccine- and non-vaccine preventable diseases in the population, effects of changes in vaccination schedules or vaccine combinations and more in-depth immunological analyses if needed.1.5 Assess contact behaviour among the general Dutch population for potential effects on transmission of infectious diseases. 1.6 Establish a resource of data and samples of the associated time period for future public health research including areas of emerging (infectious) diseases, environment and lifestyle. | — |
Secondary
| Measure | Time frame |
|---|---|
| 2.1 Assess the impact of environmental exposures in the general Dutch population on health outcomes by measuring exposures to chemical substances in serum and urine and link existing environmental data to health outcomes and changes in biological samples. 2.2 Assess the impact of lifestyle on health outcomes by for example measuring dietary status, exposure to nicotine, caffeine, alcohol and drugs.2.3 Linking 2.1, 2.2, and genetic profiles with data under 1.1-1.5. | — |
Countries
Netherlands
Contacts
Public ContactF.R.M van der Klis
RIVM
Outcome results
None listed